Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedJan 09, 2026
DataAggregated Company Financials
Companies50
  • 7D3.4%
  • 3M7.3%
  • 1Y-1.9%
  • YTD4.6%

The Biotech industry is up 3.4% in the last week, with Swedish Orphan Biovitrum up 4.0%. Overall in the last year, the industry is flat. Looking forward, earnings are forecast to grow by 30% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 09 Jan 2026SEK 215.2bSEK 38.1b-SEK 556,362,826.7534.9x-386.8x5.7x
Sun, 07 Dec 2025SEK 209.4bSEK 38.1b-SEK 603,799,286.9831.5x-346.9x5.5x
Tue, 04 Nov 2025SEK 202.9bSEK 37.3b-SEK 1,210,312,400.4038.2x-167.7x5.4x
Thu, 02 Oct 2025SEK 204.8bSEK 36.4bSEK 3.0b31.6x67.7x5.6x
Sat, 30 Aug 2025SEK 202.0bSEK 36.0bSEK 2.9b33.4x70.7x5.6x
Mon, 28 Jul 2025SEK 192.9bSEK 35.9bSEK 2.8b28.7x69.1x5.4x
Wed, 25 Jun 2025SEK 180.3bSEK 35.2bSEK 2.2b28.1x80.8x5.1x
Fri, 23 May 2025SEK 187.3bSEK 35.2bSEK 2.3b29.8x81.6x5.3x
Sun, 20 Apr 2025SEK 175.2bSEK 33.7bSEK 758.0m29x231.2x5.2x
Tue, 18 Mar 2025SEK 194.1bSEK 33.7bSEK 579.2m34.2x335.1x5.8x
Thu, 13 Feb 2025SEK 215.7bSEK 33.7bSEK 360.6m52.4x598.3x6.4x
Sat, 11 Jan 2025SEK 215.7bSEK 33.0b-SEK 4,418,532,037.77154.7x-48.8x6.5x
Mon, 09 Dec 2024SEK 214.0bSEK 33.0b-SEK 4,445,850,513.32146.4x-48.1x6.5x
Wed, 06 Nov 2024SEK 216.4bSEK 33.2b-SEK 4,479,044,648.70139.3x-48.3x6.5x
Fri, 04 Oct 2024SEK 208.7bSEK 31.4b-SEK 5,523,789,807.0948.9x-37.8x6.6x
Sun, 01 Sep 2024SEK 216.4bSEK 31.5b-SEK 5,517,537,354.7351.1x-39.2x6.9x
Tue, 30 Jul 2024SEK 197.7bSEK 31.4b-SEK 5,422,431,125.9643.6x-36.5x6.3x
Thu, 27 Jun 2024SEK 196.4bSEK 30.6b-SEK 5,517,571,098.6739.1x-35.6x6.4x
Sat, 25 May 2024SEK 193.4bSEK 30.6b-SEK 5,404,566,279.1039.4x-35.8x6.3x
Mon, 22 Apr 2024SEK 178.5bSEK 29.8b-SEK 5,265,765,392.2366.1x-33.9x6x
Wed, 20 Mar 2024SEK 183.4bSEK 29.8b-SEK 5,637,249,953.1757.4x-32.5x6.2x
Fri, 16 Feb 2024SEK 178.9bSEK 29.7b-SEK 5,673,453,859.4359.7x-31.5x6x
Sun, 14 Jan 2024SEK 190.3bSEK 28.7b-SEK 1,198,820,921.0060.5x-158.8x6.6x
Tue, 12 Dec 2023SEK 171.2bSEK 28.7b-SEK 1,200,483,096.0058.6x-142.6x6x
Thu, 09 Nov 2023SEK 159.6bSEK 28.6b-SEK 1,292,654,015.0051x-123.5x5.6x
Sat, 07 Oct 2023SEK 160.1bSEK 27.4b-SEK 2,016,886,135.0048.4x-79.4x5.9x
Mon, 04 Sep 2023SEK 155.4bSEK 27.3b-SEK 1,924,351,833.0052.5x-80.8x5.7x
Wed, 02 Aug 2023SEK 157.9bSEK 27.5b-SEK 1,533,159,176.0057.3x-103x5.7x
Fri, 30 Jun 2023SEK 159.2bSEK 26.4b-SEK 1,318,033,395.0045x-120.8x6x
Sun, 28 May 2023SEK 170.8bSEK 26.3b-SEK 1,210,350,862.0046.3x-141.1x6.5x
Tue, 25 Apr 2023SEK 172.1bSEK 25.5b-SEK 2,076,255,198.0039.8x-82.9x6.8x
Thu, 23 Mar 2023SEK 163.0bSEK 25.4b-SEK 2,030,908,008.0038.3x-80.3x6.4x
Sat, 18 Feb 2023SEK 172.6bSEK 25.3b-SEK 1,995,341,766.0026.9x-86.5x6.8x
Mon, 16 Jan 2023SEK 173.3bSEK 23.8b-SEK 1,844,159,459.0031.6x-94x7.3x
Price to Earnings Ratio

-94x


Total Market Cap: SEK 173.3bTotal Earnings: -SEK 1,844,159,459.00Total Revenue: SEK 23.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -45.9x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.1x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Revenues for these companies have grown 17% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market1.34%
Healthcare1.47%
Biotech3.41%
Biotech3.41%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 346.204.0%
+SEK 4.6b		8.2%PE9178.5x
BIOA B BioArcticSEK 332.807.1%
+SEK 2.0b		62.7%PE29.5x
VICO Vicore Pharma HoldingSEK 12.5010.6%
+SEK 337.8m		25.0%PS414x
BIOG B BioGaiaSEK 109.102.7%
+SEK 293.4m		-5.9%PE34.9x
CANTA CantargiaSEK 4.8014.7%
+SEK 152.9m		182.4%PE8.5x

Latest News

SOBI
SEK 346.20
Swedish Orphan Biovitrum
7D
4.0%
1Y
8.2%

SOBI: Pipeline Milestones And Buy Rating Are Expected To Shape Returns

Analysts have raised their price target on Swedish Orphan Biovitrum from SEK 367.09 to about SEK 371.18, reflecting updated assumptions around discount rate, profit margin and a slightly higher future P/E, along with recent research that included an upgrade to Buy with a SEK 370 target. Analyst Commentary Bullish Takeaways Bullish analysts point to the SEK 370 price target as support for the view that the revised assumptions on discount rate, profit margin and future P/E still leave room for upside versus the previous framework.
BIOG B
SEK 109.10
BioGaia
7D
2.7%
1Y
-5.9%

BIOG B: Serotonin Link In Gut Microbiota Will Support Higher Earnings Multiple

Analysts have lifted their fair value estimate for BioGaia from SEK 130 to SEK 140, citing updated assumptions for discount rates, revenue growth, profitability and future P/E that they see as better aligned with the company’s current outlook. What's in the News Researchers linked to BioGaia reported that specific gut bacteria can produce serotonin, a key bioactive substance in the microbiota gut brain axis, with findings published in Cell Reports (Key Developments).
VICO
SEK 12.50
Vicore Pharma Holding
7D
10.6%
1Y
25.0%
HNSA
SEK 32.76
Hansa Biopharma
7D
-4.7%
1Y
-6.5%

HNSA: Buy Initiation And FDA Filing Will Shape Upside Potential

Analysts have adjusted their price view on Hansa Biopharma from SEK 143 to SEK 111, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E, along with fresh coverage that includes a new SEK 100 target from Street research. Analyst Commentary Bullish analysts see the recent SEK 100 price target as a constructive marker for where Hansa Biopharma could trade if the company executes in line with their assumptions on revenue, margins and future P/E.
BINV
SEK 31.20
BioInvent International
7D
6.1%
1Y
-2.0%
EGTX
SEK 4.86
Egetis Therapeutics
7D
-9.0%
1Y
-28.5%
BIOA B
SEK 332.80
BioArctic
7D
7.1%
1Y
62.7%

BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks

Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.
ONCO
SEK 4.67
Oncopeptides
7D
-2.8%
1Y
194.8%

ONCO: Improved Profitability And NK Cell Platform Will Drive Long-Term Upside

Analysts have raised their price target on Oncopeptides from approximately SEK 4.50 to SEK 5.50 per share, citing expectations of stronger long term profitability, supported by higher projected profit margins and a lower future price to earnings multiple, despite slightly tempered revenue growth assumptions and a modestly higher discount rate. What's in the News Panel of leading multiple myeloma experts publishes clinical recommendations in Annals of Hematology on optimal use of Pepaxti (melflufen), reinforcing its role as an important option for relapsed, refractory multiple myeloma, including elderly and high risk patients, with a manageable safety profile (company announcement).
VITR
SEK 135.00
Vitrolife
7D
-1.5%
1Y
-35.3%

VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential

Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).
SYNACT
SEK 21.80
SynAct Pharma
7D
-3.5%
1Y
86.2%
DMYD B
SEK 11.84
Diamyd Medical
7D
5.2%
1Y
-34.5%
CANTA
SEK 4.80
Cantargia
7D
14.7%
1Y
182.4%
DEX
SEK 7.15
Dextech Medical
7D
-10.6%
1Y
68.6%
DVYSR
SEK 108.60
Devyser Diagnostics
7D
-4.9%
1Y
-8.4%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
XSPRAY
SEK 31.05
Xspray Pharma
7D
-1.3%
1Y
-10.1%